anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tuberculosis is an infectious disease which kills more than 3 million people every year. Although both a vaccine and various methods of diagnosis and treatment are available the efficacy of these measures is in urgent need of improvement, given that the number of new cases is again on the rise. Research focuses, among other things, on the characterization of antigens secreted in the early stages of the infection as they constitute the first point of contact of the immune system with the pathogen. The 40 KD-antigen discussed in this article is present $I(in vivo) as a hexamer and, despite its high molecular weight and lack of a signal sequence, is present extracellularly after only a few days of growth. Functionally it is an L-alanine dehydrogenase and reacts with the monoclonal antibody HBT-10 directed against this protein. HBT-10 was the first known antibody specific to a protein of M.tuberculosis which did not cross-react with the vaccine strain M.bovis BCG.
Plague is an infection occurring in small rodents and mammals caused by the gram-negative bacterium Yersinia pestis (Y. pestis). Transmission from rodent to man is usually by a flea vector leading to the characteristic swelling of the lymph nodes draining the region of the bite, followed by a septicaemic illness (classic bubonic plague). Human-to-human transmission can occur via droplet nuclei spread by coughing of patients with bubonic or septicaemic plague who have developed pulmonary lesions (pneumonic plague). However, cases of pulmonary transmission have also been described from household pets. In pneumonic plague symptoms of a respiratory infection develop first followed by an acute onset septicaemic illness. In the military context, the likely exposure is via the inhalation route, as a Biological Warfare Agent (BWA), and therefore protection against pneumonic plague is the paramount requirement. This is a phase 1, parallel group, single-blind study of 105 healthy adult aged 18-55, randomly assigned to one of the three cohorts and will receive the same dose of vaccines (2x) and then re-randomized at 6 months to receive either a third dose or placebo, in order to determine the safety and tolerability associated with different primary immunization doses of recombinant IM plague vaccine (rF1 and rV) antigen proteins for optimum safe dose, assess responses (both antibody and cell-mediated) following immunization, investigate the correlation between cell-mediated and antibody titers and to assess the duration of the immune responses to antigens following a third dose.
A unique method of simultaneously marking both packaging and prepackaged articles such as tablets, pills, medical devices, and the like on the fly, without the deposition of ink or other marking materials on their surfaces, and without degrading the prepackaged articles or breaching the packaging. The markings can serve as unique identifiers for each individual marked article (serial numbers), as product identifiers (bar codes), or as tamper protection (positioning symbols), or the like. One product can be provided with all three types of marking, if desired. A radiation sensitive marking material such as titanium dioxide, for example, can be provided in both the article and a markingly associated window of packaging material. The article and the window together provide a marked pair. The amount of titanium dioxide in each element of the marked pair is effective to provide a mark when exposed to an effective amount of ultraviolet laser energy so that both elements of the marked pair are marked with the same mark at the same time. The energy is emitted in a predefined pattern so as to define the desired marking pattern in each of the window and the article. Marking is effectively instantaneous, thereby permitting the target prepackaged articles to be marked while in motion to efficiently and inexpensively provide very high marking rates. Articles can be sterilized and packaged in a clean room, and then removed from the clean room to some other site where marking of both the article and the package can be accomplished.
Tracheal intubation is a common practice during general anesthesia. Laryngoscope and lightwand are two commonly used methods of tracheal intubation. The autonomic stimulation of tracheal intubation may have adverse effect to the patients and have been investigated since many years ago. Conventional methods for assessing autonomic activity include measurement of blood catecholamine levels or measuring changes of the hemodynamic variables such as heart rate and blood pressure. The former is invasive and noncontinuous, and the latter is nonspecific and not accurate. Heart rate variability, a parameter derived from the spectral power of RR interval sequence in the ECG, is a non-invasive but direct measurement of autonomic activity. It is ideal and we will use this in the current research for comparing the autonomic activation during tracheal intubation of the two different methods.

Totally 60 ASA class I-II patients aged 18-65 years will be recruited. 40 of these are scheduled for various kind of surgery needing general anesthesia with tracheal intubation of single lumen tube. These 40 patients will be randomly assigned into group A and B, each with 20 patients. In group A the tracheal intubation will be performed by laryngoscope, and in group B the intubation performed by lightwand. The other 20 patients of the study, the group C, are scheduled for operations needing intubation of double lumen endobronchial cath. The intubation will be performed by laryngoscope.

ECG wil be recorded from at least 5 minutes before induction of general anesthesia and continue to at least 10 minutes after tracheal intubation. The induction and maintenance of anesthesia will performed as routine practice. The ECG records wil be analyzed offline. Power spectrum wil be generated by time-frequency analysis and the heart rate variability parameters at three periods (1)preoperation baseline (2) pre-intubation and (3) immediately post-intubation will be calculated and compared among the three groups.
Under the general hypothesis that atherosclerosis is a systemic disease; the purpose of this protocol is to compare coronary artery atherosclerotic abnormalities with carotid artery abnormalities. This is an NHLBI sponsored sub study to the Pfizer sponsored trial comparing atorvastatin or the combination of atorvastatin/CETP inhibitor as treatments for patients with coronary heart disease. The primary study is a multicenter, randomized, double blind, active-controlled study which uses intracoronary ultrasound to measure coronary plaque volume during the course of treatment. The scientific value of the NHLBI sub study will be the comparison of atherosclerotic abnormalities in two different vascular beds, the coronary artery and the carotid arteries. This study will examine correlations between invasive coronary measurements by intravascular ultrasound (IVUS), with 2-dimensional measurements of wall thickness by carotid intimal medial wall thickness (IMT), and with 3-dimensional measurements of carotid wall volume by MRI and 3D ultrasound. Secondary analysis will probe whether carotid plaque characteristics can predict atheroma regression. Secondary analysis will also assess the ability of noninvasive carotid measures to predict the degree of coronary regression determined in the coronary arteries by IVUS. It is important to note that the NHLBI study design remains blinded to the treatment group a subject is enrolled in since the sample size for a single center study is too small to detect the conservatively estimated additional benefit of combination atorvastatin/CETP inhibitor treatment over the already effective atorvastatin alone. Thus, the NHLBI sub study is primarily a pathophysiological study correlating carotid and coronary atherosclerotic changes as well as a technological comparison of IVU, carotid IMT, and carotid vessel wall volume by MRI. If successful, this study could provide the framework for following treatment trials of this nature with noninvasive tools, either ultrasound or MRI, in place of the accurate but invasive IVUS.
Serratia marcescens is a global opportunistic pathogen. In vitro cytotoxicity of this bacterium is mainly related to metalloprotease serralysin (PrtS) activity. Proteolytic capability varies among the different isolates. Here, we characterized protease production and transcriptional regulators at 37°C of two S. marcescens isolates from bronchial expectorations, HU1848 and SmUNAM836. As a reference strain the insect pathogen S. marcescens Db10 was included. Zymography of supernatant cultures revealed a single (SmUNAM836) or double proteolytic zones (HU1848 and Db10). Mass spectrometry confirmed the identity of PrtS and the serralysin-like protease SlpB from supernatant samples. Elevated proteolytic activity and prtS expression were evidenced in the HU1848 strain through azocasein degradation and qRT-PCR, respectively. Evaluation of transcriptional regulators revealed higher eepR expression in HU1848, whereas cpxR and hexS transcriptional levels were similar between studied strains. Higher eepR expression in HU1848 was further confirmed through an in vivo transcriptional assay. Moreover, two putative CpxR binding motifs were identified within the eepR regulatory region. EMSA validated the interaction of CpxR with both motifs. The evaluation of eepR transcription in a cpxR deletion strain indicated that CpxR negatively regulates eepR. Sequence conservation suggests that regulation of eepR by CpxR is common along S. marcescens species. Overall, our data incorporates CpxR to the complex regulatory mechanisms governing eepR expression and associates the increased proteolytic activity of the HU1848 strain with higher eepR transcription. Based on the global impact of EepR in secondary metabolites production, our work contributes to understanding virulence factors variances across S. marcescens isolates.
Although durvalumab has not been approved as treatment for HCC, similar PD1 blockade agents such as nivolumab and pembrolizumab have gain approval as salvage therapy for advanced HCC. The investigators will enroll 43 patients with active (defined as serum viral load \> 2000 IU/mL) chronic HBV infection (defined as positive serum HBV surface antigen). All patients would receive entecavir within 7 days of initiation of durvalumab treatment. Durvalumab 1500 mg would be given intravenously every 4 weeks until confirmed disease progression, intolerable side effects, or completion of 24 treatment. Tumor assessment will be performed every 8-12 weeks. HBV viral load will be monitored at least once per month. Entecavir treatment will be continued at least 6 months after discontinuation of durvalumab treatment.
The invention discloses a dynamic function connection classification method based on a convolution bidirectional gating circulation unit, and belongs to the field of brain science research. The method comprises the following steps: extracting multi-scale topological features; extracting two-way dependent space-time characteristics; two-way dependence space-time feature fusion. Firstly, a convolutional neural network is used for extracting multi-scale topological features from a functional connection network at each moment. It then utilizes a bi-directional gating loop unit to extract bi-directionally dependent spatiotemporal features from the multi-scale topological feature time series. Finally, the method utilizes the one-dimensional convolutional neural network to fuse the front and the back space-time characteristics to obtain the combined space-time characteristics for classification, and the combined space-time characteristics are input into a fully-connected neural network classifier for classification. Experimental results on multiple brain disease datasets indicate that the proposed method has better classification performance than other dynamic functional connection classification methods.
This study aims at the improvement of muscular function by physical exercise in prefrail elderly persons. Prefrail participants are recruited according to the frailty score of Fried. Taking into account, that vitamin D supplementation reduces falls and improves muscle strength in older people, all participants are supplemented by vitamin D. Two different training methods are tested.

After a run-in period of supplementation of vitamin D for two months, participants will be randomized into three different equally sized groups (n=25): Group A will receive power training. Group B will have progressive strength training. Group C will serve as a control group. They will receive a consultation about leading a healthy life with special attention being paid to nutrition and physical activity. The intervention period lasts for 12 weeks. The 60 minutes training sessions will be held two times a week by members of the Institute of Sport Science and Sports of the University of Erlangen-Nuremberg. Follow-up visits are scheduled three and six months after intervention period.
PURPOSE:To provide the titled external drug containing nicardipin hydrochloride useful as a coronary vasodilator, etc. in a form having excellent transcutaneous absorbability, by dissolving nicardipin hydrochloride in a mixture of a sorbitan medium-fatty acid ester, propylene glycol, urea, etc., and forming the mixture to an externally applicable form. CONSTITUTION:Nicardipin hydrochloride is dissolved or dispersed in a liquid mixture of a sorbitan medium-fatty acid ester (e.g. sorbitan monocaproic acid ester, etc.), propylene glycol, and a urea compound (e.g. urea, thiourea, etc.), and the solution is formed to an externally applicable form. An external drug containing nicardipin hydrochloride having excellent transcutaneous absorption can be prepared by this process. The storage stability and the transcutaneous absorbability of the drug can be improved by compounding the above drug composition with an agent to suppress the crystallization of nicardipin hydrochloride (e.g. propylene glycol didecanoate, polyoxyethylene hardened castor oil, etc.).
All 50 states and the District of Columbia are performing newborn screening for cystic fibrosis (CF). Infants who have a positive newborn screen require follow-up with a sweat test. Gibson-Cooke Quantitative Pilocarpine Iontophoresis (GCQPIT) requires collecting sweat in microbore tubing or on gauze/filter paper and analyzing sweat using a chloridometer. This test has many difficulties including specimens that are quantity not sufficient (QNS), many steps of pipetting solutions in the laboratory, and the need for a chloridometer to analyze sweat chloride concentration. The only manufacturer of a chloridometer has ceased production of this instrument. The CF Quantum® Sweat Test System (CFQT) overcomes all of the difficulties of GCQPIT. This pilot study will determine if the CFQT provides results that are equivalent to GCQPIT.
Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
FIELD: medicine. SUBSTANCE: method involves removing bile from patient by applying external drainage of biliary tracts. Donor bile is additionally used. Then bile sorption is carried out. Sorption being accomplished, the bile is lyophilized and packed in solid gelatin capsules of 200 g. The preparation is to be administered in the amount of 6-10 capsules every day in 3-4 doses 10 min before meals during 3-13 days. EFFECT: reduced risk of treatment complications. 2 tbl
Seizures and other central nervous system (CNS) adverse experiences have been reported during treatment with Ertapenem for Injection [see Adverse Reactions ( 6.1)] . During clinical investigations in adult patients treated with Ertapenem for Injection (1 g once a day), seizures, irrespective of drug relationship, occurred in 0.5% of patients during study therapy plus 14-day follow-up period [see Adverse Reactions ( 6.1)] . These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function. Close adherence to the recommended dosage regimen is urged, especially in patients with known factors that predispose to convulsive activity. Anticonvulsant therapy should be continued in patients with known seizure disorders. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of Ertapenem for Injection re-examined to determine whether it should be decreased or discontinued.
Lipotoxicity refers to the accumulation of lipids in tissues other than adipose tissue (body fat). It is one of the major pathophysiological mechanisms responsible for the progression of diabetes complications such as non-alcoholic fatty liver disease and diabetic nephropathy. Accumulating evidence indicates that lipotoxicity also contributes significantly to the toxic effects of diabetes on periodontitis. Therefore, we reviewed the current in vivo, in vitro, and clinical evidence of the detrimental effects of lipotoxicity on periodontitis, focusing on its molecular mechanisms, especially oxidative and endoplasmic reticulum stress, inflammation, ceramides, adipokines, and programmed cell death pathways. By elucidating potential therapeutic strategies targeting lipotoxicity and describing their associated mechanisms and clinical outcomes, including metformin, statins, liraglutide, adiponectin, and omega-3 PUFA, this review seeks to provide a more comprehensive and effective treatment framework against diabetes-associated periodontitis. Furthermore, the challenges and future research directions are proposed, aiming to contribute to a more profound understanding of the impact of lipotoxicity on periodontitis.
The patients in control group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires: visual analogue scale, McGill Pain questionnaire, Wound Quality of Life Index, Health Quality of Life Questionnaire, Beck depression and Beck anxiety inventory.
Those receiving age-appropriate appetite stimulants will be provided either cyproheptadine or olanzapine. Subjects will be given cyproheptadine if they fall between the ages of 2-12 years of age and olanzapine if they are \>12 years of age or older.
BACKGROUND: Though the primary goal for limb length discrepancy (LLD) management is to equalize the leg lengths, symmetry between corresponding long bones is usually not achieved, leading to knee height asymmetry (KHA). To date, there is minimal information on what effect KHA has on gait biomechanics and joint loading. Thus, the purpose of this study is to determine the impact of KHA on gait biomechanics.
METHODS: Seventeen subjects with KHA after limb equalizing surgery and 10 healthy controls were enrolled. Subjects participated in 3D gait analysis collected using self-selected speed. Lower extremity kinematics, kinetics, work generated/absorbed, and total work were calculated. Standing lower limb x-rays and scanograms were used to measure LLD and calculate the tibia-to-femur (TF) ratio for each limb. Two sample t tests were used to compare differences in standing LLD, TF ratio, and work between groups. Bivariate correlation using Pearson correlation coefficients was conducted between TF ratio and total mechanical work, as well as between knee height asymmetry indices and total work asymmetry (α=0.05).
RESULTS: Among participants, there were no differences between LLD; however, there were differences between TF ratio and knee height asymmetry. We found a nonsignificant relationship between TF ratio and total mechanical work for individual lower extremities. Therefore, the length of individual bones (TF ratio) relative to each other within the individual lower extremity was not associated with the amount of work produced. However, when a difference exists between sides (asymmetry, ie, TF ratio asymmetry), there were associated differences in work (work asymmetry) produced between sides (r=0.54, P =0.003). In other words, greater knee height asymmetry between limbs resulted in more asymmetrical mechanical work during walking.
CONCLUSIONS: These findings may have implications for the management of LLD. Asymmetrical total mechanical work could lead to atypical joint loading during gait. Surgeons may want to consider prioritizing achieving knee height symmetry as a postoperative goal when correcting limb length discrepancy.
LEVEL OF EVIDENCE: Level III, Case Control Study.
Clonal expansion of B-cells, from the early stages of monoclonal B-cell lymphocytosis through to chronic lymphocytic leukemia (CLL), and then in some cases to Richter's syndrome (RS) provides a comprehensive model of cancer evolution, notable for the marked morphological transformation and distinct clinical phenotypes. High-throughput sequencing of large cohorts of patients and single-cell studies have generated a molecular map of CLL and more recently, of RS, yielding fundamental insights into these diseases and of clonal evolution. A selection of CLL driver genes have been functionally interrogated to yield novel insights into the biology of CLL. Such findings have the potential to impact patient care through risk stratification, treatment selection and drug discovery. However, this molecular map remains incomplete, with extant questions concerning the origin of the B-cell clone, the role of the TME, inter- and intra-compartmental heterogeneity and of therapeutic resistance mechanisms. Through the application of multi-modal single-cell technologies across tissues, disease states and clinical contexts, these questions can now be addressed with the answers holding great promise of generating translatable knowledge to improve patient care.